Skip to content
Pipeline

Therapeutic Candidates

Programs
Early Discovery E Disc
Late Discovery L Disc
Lead Optimization L Opt
IND-Enabling IND
Clinical Clin
Oncology
Programs: IBIO-101

This IL-2-sparing anti-CD25 antibody aims to reduce tumor growth by selectively depleting immunosuppressive regulatory T cells without affecting cancer-killing effector T cells. It’s being investigated as a fast follower to Hoffman-La Roche’s RG6292 molecule, with potential indications including solid tumors, hairy cell leukemia, lymphoma, and head and neck cancers.

LEARN MORE

Programs: Endostatin E4

The Endostatin E4 peptide is being investigated for its potential to attack cancer-associated fibroblasts, one of the most abundant and critical tumor tissue components, often associated with variable responses to chemotherapy and immunotherapy.

Programs: Trop-2 x CD3*

TROP-2 (Trophoblast cell-surface antigen 2) is an overexpressed cell surface protein in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers. It plays a crucial role in promoting tumor growth, survival, and metastasis by regulating cell signaling pathways, adhesion, and epithelial-mesenchymal transition. Targeting TROP-2 with bispecific antibodies aims to engage the immune system to treat TROP-2-positive cancers selectively and effectively.

Learn More

Programs: MUC16

MUC16 is a tumor-associated epitope that is over-expressed and shed by tumor cells, making it difficult to kill the tumor. The antibody being investigated binds to nearby epitopes that are not shed to maintain activity against the tumor.

Learn More

Programs: Target 5
Immuno-Oncology
Programs: EGFRvIII

This anti-EGFRvIII antibody is being investigated to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue. The novel antibody has high antibody-dependent cellular cytotoxicity (ADCC), potentially reducing toxicity and expanding the therapeutic window.

LEARN MORE

Programs: CCR8

This potential candidate is designed to selectively bind to CCR8, a protein highly expressed by regulatory T cells in the tumor microenvironment, without killing its closely related neighbor, CCR4. When CCR8 and regulatory T cells are depleted without killing CCR4, CCR4 triggers an innate immune response to selectively target and kill tumors. This target can potentially treat a broad range of cancers, alone and in combination with checkpoint inhibitors.

LEARN MORE

Programs: Target 8
Immuno-Oncology
Autoimmune
Programs: PD-1

This PD-1 agonist is being investigated to alleviate inflammatory disease by agonizing PD-1 without blocking PD-L1, a protein that may play a role in suppressing the adaptive immune system. This could restore T cell suppression in the treatment of rheumatoid arthritis and other inflammatory diseases.

LEARN MORE

* Developed with EngageTx bispecific platform

iBio’s technology stack delivers precision antibodies designed to minimize downstream development risk through AI-guided epitope steering and optimization of monoclonal and next-gen CD3 T-cell engager bispecific antibodies. Our team of AI and machine-learning scientists, along with our drug hunters, are engineering antibodies for hard-to-drug targets, primarily in immunotherapy for cancer. We have a pipeline of 8 immuno-oncology therapeutics and a therapeutic candidate with the potential to treat various autoimmune diseases. Driven by our commitment to innovation, we are actively developing select programs internally while maintaining the flexibility to explore collaborative opportunities through licensing our programs to strategic partners.

We have one additional candidate available for partnering – IBIO-400 for Classical Swine Fever.

We are excited about the potential therapeutic benefits of our proprietary pipeline and are looking for partners who share our passion for bringing innovative treatments to advance healthcare and improve patient lives.

To learn more about our pipeline candidates and potential partnership opportunities, please contact us.

The IBIO-100 candidates for idiopathic pulmonary fibrosis [IPF] and systemic sclerosis have been shown to address symptoms of fibrosis in highly diseased human tissue in addition to efficacy in preclinical models. Based upon work by Dr. Carol Feghali-Bostwick, the lead candidates are a fusion of the endostatin derived E4 antifibrotic peptide to the hinge and heave chain of human IgG1. Orphan drug designation was granted by the US FDA for the systemic scleroderma indication.
In collaboration with the Institute of Infectious Animal Diseases (IIAD), within the Texas A&M University System and Kansas State University, we used FastPharming®, iBio’s plant-based manufacturing system, to develop a safe and effective subunit vaccine1 capable of differentiating infected from vaccinated animals (DIVA), a key consideration for restoration of trade status2. Formulated in cost-effective oil-in-water emulsion adjuvants, IBIO-400 studies demonstrated that a single-dose of the adjuvanted, plant-made CSF E2 subunit vaccine provides protection in challenged pigs and is accompanied by strong virus neutralization antibody response.

References

  1. Laughlin, R.C. et al. (2019) “Plant‐made E2 glycoprotein single‐dose vaccine protects pigs against classical swine fever.” Plant Biotechnol J. 17(2):410-420.
  2. “Classical Swine Fever Response Plan: The Red Book”. Foreign Animal Disease Preparedness and Response Plan. National Center for Animal Health Emergency Management. United States Department of Agriculture, Animal and Plant Health Inspection Service. March 2013.
Top